Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: paricalcitol capsules Clear all
Completed Phase 4 Interventional Results available

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

NCT03588884
View directory record Official record
Conditions
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
Interventions
Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 20, 2026, 7:36 PM EDT
Withdrawn Not applicable Interventional

The Effects of Active VItamin D on Left Atrial Volume Index

NCT01630408
View directory record Official record
Conditions
Heart Failure
Interventions
Paricalcitol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 20, 2026, 7:36 PM EDT
Active, not recruiting Early Phase 1 Interventional

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

NCT05664880
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Paricalcitol, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)

NCT00048516
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
paricalcitol capsule
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
16
States / cities
Los Angeles, California • Riverside, California • Simi Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

NCT00417612
View directory record Official record
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

NCT00421733
View directory record Official record
Conditions
Diabetic Nephropathy, Chronic Kidney Disease
Interventions
Zemplar (paricalcitol) capsules, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
27
States / cities
Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 4 Interventional Results available

Vitamin D and Coronary Calcification Study

NCT00752102
View directory record Official record
Conditions
Chronic Kidney Disease, Vitamin D Deficiency, Coronary Calcification, Disorders of Calcium and Bone Metabolism
Interventions
Calcitriol (Rocaltrol®), Paricalcitol
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
25 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

NCT00048451
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
paricalcitol
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
18
States / cities
Tucson, Arizona • Pasadena, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 20, 2026, 7:36 PM EDT
Terminated No phase listed Observational Results available

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

NCT01134315
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End-Stage Renal Disease
Interventions
Paricalcitol, Calcitriol
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Up to 16 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Gainesville, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 20, 2026, 7:36 PM EDT
Terminated Phase 2 Interventional Results available

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

NCT00634582
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional

Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis

NCT00091975
View directory record Official record
Conditions
Kidney Disease
Interventions
Zemplar Capsule
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
16
States / cities
San Diego, California • Washington D.C., District of Columbia • Fort Meyers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Results available

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

NCT00497146
View directory record Official record
Conditions
Chronic Kidney Disease, Left Ventricular Hypertrophy
Interventions
paricalcitol, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
30
States / cities
Phoenix, Arizona • Tempe, Arizona • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

NCT00646035
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
paricalcitol capsules
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
22
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2008 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

NCT00463021
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol (doxercalciferol capsules), Zemplar (paricalcitol injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
8
States / cities
Downey, California • Paramount, California • Hudson, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

NCT00048438
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
paricalcitol
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
17
States / cities
Orange, California • Thornton, Colorado • Hudson, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery

NCT01138475
View directory record Official record
Conditions
Gastric Bypass, Parathyroid Hormone
Interventions
Paricalcitol, Cholecalciferol, Placebo
Drug
Lead sponsor
Kerstyn C. Zalesin, M.D.
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 20, 2026, 7:36 PM EDT
Completed No phase listed Observational

Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients

NCT02018133
View directory record Official record
Conditions
CKD Stage 3/4
Interventions
Vitamin D 2mg daily for 2 weeks oral paricalcitol, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

NCT00977080
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions
Paricalcitol, Cinacalcet
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 20, 2026, 7:36 PM EDT
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 20, 2026, 7:36 PM EDT